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Abstract: Diabetes distress (DD) disproportionately affects vulnerable people with type 2 
diabetes mellitus and interventions targeting this population are therefore relevant. A systematic 
review and meta-analysis was performed to assess the evidence for an effect of psychosocial 
interventions for reducing DD, and, secondly HbA1c, depression, and health-related quality of 
life in vulnerable people with type 2 diabetes mellitus. Vulnerability encompasses poor glycemic 
control (HbA1c >7.5%) and at least one additional risk factor for poor diabetes outcomes such 
as low educational level, comorbidity, and risky lifestyle behavior. The interventions should be 
theoretically founded and include cognition- or emotion-focused elements. We systematically 
searched four databases for articles published between January 1995 and March 2018. Eigh-
teen studies testing a variety of psychosocial interventions in 4,066 patients were included. We 
adhered to the Cochrane methodology and PRISMA guidelines. Review Manager 5.3 was used 
for data extraction and risk of bias assessment, and Grades of Recommendation, Assessment, 
Development and Evaluation for assessing the quality of the evidence. Data were pooled using 
the fixed or random effects method as appropriate. We investigated effects of individual vs 
group, intensive vs brief interventions, and interventions with and without motivational inter-
viewing in subgroup analyses. To assess the robustness of effect estimates, sensitivity analyses 
excluding studies with high risk of bias and attrition >20% were conducted. We found low to 
moderate quality evidence for a significant small effect of psychosocial interventions on DD, 
and very low to moderate quality evidence for no effect on HbA1c, both outcomes assessed at 
3, 6, 12, and 24 months follow-up. The effect on depression was small, while there was no effect 
on health-related quality of life. Exploratory subgroup analyses suggested that interventions 
using motivational interviewing and individual interventions were associated with incremental 
effects on DD. Likewise, intensive interventions were associated with significant reductions in 
both DD and HbA1c.
Keywords: diabetes distress, HbA1c, meta-analysis, psychosocial interventions, type 2 diabetes, 
vulnerable populations
Introduction
The daily demands of people living with type 2 diabetes mellitus (T2DM) may 
increase the risk of diabetes distress (DD).1 DD is a condition of stressful feelings 
associated with the challenges of managing diabetes and concerns related to dia-
betic complications.1 The prevalence of DD ranges from 18% to 35% in a general 
population with T2DM,2,3 but is substantially higher in ethnic minority subgroups 
and in hospitalized patients.4 DD is associated with a longer duration of diabetes 
diagnosis, reduced adherence to treatment5 and glycemic control6 leading to an 
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elevated risk of diabetic complications.5,7,8 Additionally, 
DD may progress to depression,9 potentially leading to risk 
of premature death.10 DD is distinct from depression by 
being far more prevalent11 and directly related to diabetes 
management.11–13 It is particularly relevant to address DD 
given the high prevalence and association with diabetes 
management in people with T2DM.13
DD disproportionately affects vulnerable people with 
T2DM.2 Vulnerable people are those requiring the utmost 
care and consideration, and who are often characterized by 
factors associated with an increased risk of DD,14 such as low 
educational level, comorbidity,3 and poor glycemic control, 
which is overrepresented in this population.15 Likewise, 
living alone and risky lifestyle behaviors such as smoking, 
unhealthy diet, and sedentary lifestyle are more often present 
in people with T2DM suffering severe and prolonged DD.2 
The clustering of risk factors for DD can increase hormonal 
stressors, thereby further affecting blood glucose.16 Indeed, 
trajectories of DD appear most severe and persistent in vul-
nerable people with T2DM.2 Consequently, consideration of 
DD specifically in vulnerable people with T2DM is relevant 
for self-management6 and prevention of complications in an 
already susceptible group.5
In many clinical settings, interventions for reducing DD 
are not standard care.11 This suggests that caregivers and 
current health care interventions fail to sufficiently embrace 
the needs of vulnerable people with T2DM.17 The relation-
ship between DD, self-management, and glycemic control 
has primarily been described associatively.12,18 Hence, the 
causal pathways among these concepts remain unclear.19,20 
Nevertheless, we hypothesize that interventions specifically 
targeted toward reducing DD in vulnerable people with 
T2DM, might potentially improve glycemic control. Due 
to the complex psychosocial and pathophysiological factors 
associated with the increased risk of DD among vulnerable 
people with T2DM, we contend that interventions including 
a psychosocial approach might better alleviate DD.20 Recent 
reviews of interventions for reducing diabetes-related distress 
focused on effects in general diabetes populations rather 
than vulnerable populations.20,21 Given the susceptibility of 
vulnerable people with T2DM to increased levels of DD and 
diabetic complications, the current review therefore focuses 
specifically on existing evidence for interventions targeting 
this subgroup of people.22,23
Objective
To examine the evidence for an effect of psychosocial 
interventions vs standard care for reducing DD and HbA1c, 
depression, and health-related quality of life (HRQOL) in 
vulnerable people with T2DM.
Materials and methods
This is a systematic review adhering to Cochrane meth-
odology. The review was registered in PROSPERO (The 
International Prospective Register of Systematic Reviews) 
with registration number CRD42018064454 and reported 
according to the PRISMA guidelines.24
Types of studies
We included parallel group randomized clinical trials (RCTs) 
assessing DD as either a primary or secondary outcome. 
Exclusion criteria were as follow: cluster-randomized trials 
due to the potential lack of sensitivity to individual vulner-
ability characteristics,25 cross-over randomized trials, and 
nonrandomized controlled trials.
Participants
Participants were vulnerable people with type 2 diabetes 
duration for more than 1 year, ≥18 years, and HbA1c >7.5% 
(58 mmol/mol) at baseline. Vulnerability was defined as in 
the included studies, but including at least one or more of 
the following criteria: low socioeconomic status, low health 
literacy, Hispanic, African-American or other ethnic origin 
predisposed to an elevated risk of T2DM,26 comorbidity, or 
risky lifestyle defined as body mass index >30, sedentary 
lifestyle, smoking, or alcohol use exceeding 7 units weekly 
for women and 14 units weekly for men. The vulnerability 
criteria were informed by recommendations in the PROG-
RESS27 PLUS framework, which is an “equity lens” also 
applied by the Cochrane Collaboration. The PLUS edition 
includes individual characteristics such as lifestyle behav-
iors. We excluded studies including both type 2 and type 1 
diabetes as no socioeconomic gradient has been described 
in type 1 diabetes.28
Types of interventions
Psychosocial interventions that were emotion focused and/
or cognition focused and administered person-to-person, in 
groups, or digitally, by peers, caregivers or health care profes-
sionals, either alone or in combination, for reducing DD in 
vulnerable people with T2DM. Emotion-focused interven-
tions aim to address patients’ self-management practices and 
thereby influence health outcomes,29 while cognition-focused 
interventions involve education and acquisition of diabetes-
related skill training. The theoretical foundations underlying 
interventions should be prespecified in the methods section 
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or study protocol. Included interventions could be brief or 
intensive and delivered in health care or homecare settings.
Controls
Usual care as defined in included studies. If studies had 
more than one arm, the arm most similar to usual care was 
selected as the control.
Outcomes
Primary outcome
DD assessed by Problem Areas in Diabetes (PAID)1 or the 
Diabetes Distress Scale (DDS) at 3, 6, 12, and 24 months.32 In 
DDS, mean item scores of 2.0–2.9 indicate moderate distress, 
and scores >3 indicate clinically important distress requiring 
intervention.22 For the validated 20-item PAID scale, scores 
>40 indicate clinically important distress.33
Secondary outcomes
HbA1c measured at 3, 6, 12, and 24 months follow-up. For 
studies where follow-up time points did not match exactly, 
data from the closest time point were included. Depression 
was measured with validated instruments such as Patient 
Health Questionnaire (PHQ-9)34 at the longest follow-
up. HRQOL was measured with validated instruments or 
diabetes-specific instruments such as Diabetes Quality of 
Life11 at the longest follow-up.
Search strategy
We searched PubMed/Medline, EMBASE, CINAHL, and Psy-
cINFO using different combinations in a search matrix based 
on the PICO (patient, intervention, comparison, outcomes) 
format sans comparisons. The latest search was performed 
on June 19, 2017 supplemented with ongoing alerts from the 
databases when new studies within the search matrix were 
published (Table 1). We ended inclusion on March 31, 2018.
We included studies published in English from 1995 and 
onward. The temporal limitation was chosen to coincide with 
the development of the PAID instrument in 1995.1 Gray lit-
erature and reference lists of included studies were screened. 
Reference lists of reviews and meta-analyses retrieved from 
the searches were also screened. We screened the search 
results in Covidence Systematic Review Software.35
Identification of relevant studies
The first and last authors (ASM, TT) independently screened 
titles and abstracts for eligibility using the following order of 
importance: RCT, T2DM, DD measured by DDS or PAID, 
and vulnerable population. Thus, the first “no” was stated 
as reason for exclusion. We were not masked to authors or 
journals during the screening process.
Data extraction and management
Characteristics of the included studies were individually 
extracted by ASM and GK and included the following: author, 
title, and year published; Methods: design including number 
of trial groups, country, and publication date; Participants: 
number at baseline and follow-up, vulnerability criteria, mean 
age, mean duration of T2DM, type of treatment (lifestyle, 
tablets, insulin), comorbidity, and diabetes-related compli-
cations. Intervention: setting, intensity, delivery, deliverer 
involved and training/quality control.
Risk of bias in individual studies
ASM, GK, and TT independently assessed risk of bias in 
included studies using the Cochrane Collaboration’s Risk of 
Bias Tool.36 Due to the nature of the intervention, blinding 
of participants and staff was not considered feasible. We 
considered DD, HRQOL, and depression at high risk of 
detection bias due to lack of blinding, whereas HbA1was 
considered at low risk. Disagreements were discussed 
Table 1 Literature search
# Keywords Inclusion
1 Patients Type 2 diabetes; type 2 diabetes mellitus; diabetes, type 2; T2DM; diabetes T2; diabetes 
mellitus; vulnerable population [MeSH]; diabetes mellitus, type 2 [MeSH]
2 interventions Psychological intervention; psychological feedback; psychotherapy; psychological techniques; 
digital intervention; internet; cognitive focused intervention; cognitive intervention; cognitive 
therapy; cognitive behavior therapy; behavioral intervention; emotional focused intervention; 
cognitive behavior therapies [MeSH term]; feedback, psychological
3 Outcomes Diabetes distress; distress; diabetes-related distress; problem areas in diabetes; Diabetes 
distress scale; PAiD; DDS; HbA1c; hb A1c; glycosylated hemoglobin A; medication adherence 
[MeSH]; health related quality of life; quality of life [MeSH]; patient compliance [MeSH]
# 1 AND 2 AND 3.
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among authors until consensus was reached. We attempted 
to retrieve protocols in clinicaltrials.gov or published pro-
tocols for all included studies to assess potential selective 
reporting. In studies with missing information, the authors 
were contacted.
Data analysis
Meta-analyses were performed using available case analy-
sis and the fixed or random effects method as appropriate. 
The meta-analyses were pairwise and were weighted by the 
inverse variance. We assessed the degree of heterogeneity 
using the I2 statistic which measures the percentage of vari-
ability in effect estimates due to heterogeneity rather than 
sampling error.25 If I2 >60%, we used the random effects 
method. We used the Mean Difference (MD) with 95% CI 
to assess effects of interventions on continuous outcomes. 
If different instruments were used, we used the Standardized 
Mean Difference (SMD). On DD and HbA1c, between-
groups differences at 3, 6, 12, and 24 months follow-up 
were extracted. On depression and HRQOL, between-groups 
differences at longest follow-up were used. To increase 
transparency, risk of bias ratings and meta-analyses were 
displayed together. We investigated the risk of publication 
bias using funnel plots,37 and data analysis was conducted 
with Review Manager 5.3.
Subgroup analysis
The subgroup analyses are moderator analyses that explore 
effect heterogeneity. Results from subgroup analyses should 
therefore be interpreted cautiously.25 The following explor-
atory subgroup analyses were planned: 1) effect of brief (≤4 
sessions) vs intensive (>4 sessions) interventions, 2) group 
vs individual interventions, and 3) motivational interviewing 
vs other interventions, all on DD and HbA1c at the longest 
follow-up. The exponential increase in diabetes-related health 
care expenditures makes it relevant to investigate the effect 
of less time-consuming interventions38 such as brief and 
group interventions.
Motivational interviewing may potentially be associated 
with greater reductions in DD and HbA1c than interventions 
not including motivational interviewing in people with both 
type 1 and type 2 diabetes.21 It is relevant to explore whether 
this is also the case when focusing specifically on vulnerable 
people with T2DM.
Sensitivity analysis
We planned to do two sensitivity analyses of the robustness of 
the effect estimate for the primary outcome DD: 1) excluding 
studies with high risk of bias (minimum one high risk of bias 
rating) and 2) excluding studies with high attrition (≥20%).
Quality of evidence
We assessed the overall quality of the evidence for the 
primary outcome DD and the secondary outcomes HbA1c, 
depression, and HRQOL using the Grades of Recommenda-
tion, Assessment, Development and Evaluation (GRADE). 
This involved consideration of risk of bias, indirectness, 
inconsistency, imprecision, and publication bias. The qual-
ity of the evidence was rated as high, moderate, low, or very 
low.39 Two authors, ASM and TT, evaluated the quality of the 
evidence using GRADEpro GDT. Potential disagreements 
were solved by an arbiter (IE or TJ).
Results
The search yielded 5,035 potentially relevant studies. Of 
these, 4,721 were obviously irrelevant, leaving 314 stud-
ies that were retrieved for full-text assessment. In total, 18 
RCTs involving initial recruitment of 4,066 participants were 
included. Thirteen studies were protocols for “ongoing stud-
ies”. Studies were primarily excluded due to not measuring 
DD, wrong design or intervention (Figure 1).
Characteristics of included studies
Sample sizes ranged from 47 to 623.40,41 Sixteen studies origi-
nated from the United States with a concentration of studies 
from deprived areas in Detroit42,43 and Boston.44,45 One study 
was conducted in Germany46 and one in India.47 Hospital set-
tings were represented in 5 studies and community settings 
in 13. The studies were published in 2004–2017. Participants 
were primarily from socioeconomically deprived inner-city 
areas. Nine studies uniquely included patients from His-
panic,48–51 African American,42,43,52,53 or Hawaiian or Samoan 
origin.40 In the remaining studies, participants fulfilled our 
vulnerability criteria primarily due to a high degree of obesity, 
comorbidity, and/or low educational level (Table 2). At base-
line, mean age was 56±4 and mean duration of T2DM was 
11±2.5 years. DD was measured with DDS in two studies50,54 
and with PAID in 16 studies. Baseline mean DD measured 
by the 20-item PAID scale was 39±10.8. The five-item short 
version of PAID was used in three studies.42,47,49 Mean HbA1c 
at baseline was 8.7% (72±7.7 mmol/mol).
interventions
The interventions included combined cognition- and emo-
tion-focused interventions: social support, primarily support 
groups, some with culturally sensitive elements40,43,48,50 in 
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combination with decision support tools,42 conversation 
maps,41,45 coaching,55 coping skills training and stress 
management,49,53 empowerment training47,56 and social and 
psychological training.46 One study provided a telephone 
intervention for both the person with T2DM and spouse 
addressing diabetes-related conflict management with collab-
orative problem-solving techniques.54 Another study involved 
a family member in supporting the patient using the SMART 
(Specific, Measurable, Attainable, Relevant and Time-bound) 
goal approach for behavior change with regard to healthy 
eating, physical activity, and management of diabetes-related 
distress.50 All interventions included elements of diabetes 
self-management education of varying intensity.52,57
Standard care intervention
Eleven studies provided enhanced standard care of varying 
intensity. One study sent a monthly reminder via postcard 
for 3 months,40 one sent a monthly report on diabetes 
goals and status.52 Four studies provided two diabetes 
self-management education sessions lasting 75 minutes 
by telephone,54 one 2-hour or four 1-hour group ses-
sions.45,49,57 One study provided a 90-minute introduction 
to a print version of a web decision support tool and two 
follow-up telephone calls,42 one offered free lab tests and 
consultations,47 telephone contact every second week,44 
another delivered ten diabetes education group sessions53 
or ten biweekly sessions of 90 minutes duration focusing 
on acquisition of standardized diabetes knowledge.46 Five 
studies delivered standard treatment, described as general 
information on diabetes management provided by a health 
care professional every 3–4 months. Three studies had a 
wait-list control design,43,50,55 and three studies delivered an 
intervention to all participants prior to randomization. These 
interventions entailed two telephone calls of 75 minutes 
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duration,54 or 2.5-hour diabetes education group sessions,49 
or 12 one-hour weekly group meetings.40
Deliverers
The interventions were delivered by community health work-
ers ethnically matched to patients,42,43 nurse case managers,51 
certified diabetes educators40,46 in combination with a spouse54 
or family member,50 nurses and dieticians48 smartphone 
applications combined with support from health care pro-
viders,47 web/telephone,44 or telephone.54 In five studies, the 
deliverers were trained in motivational interviewing.42,43,51,56,57 
The training, fidelity, and quality assessment of delivery 
were most comprehensively described in interventions using 
motivational interviewing. In these studies, initial training 
ranged from 2 days57 to 80 hours42,51 with ongoing supervi-
sion of fidelity by use of validated instruments such as the 
Behavior Change Counseling Index51 or the Motivational 
Interviewing Skills Code.57
Risk of bias
We chose to pool all studies in the meta-analysis and provide a 
narrative description of risk of bias. We judged this approach 
to be sound as no studies were judged at high risk of selection 
bias. Moreover, we performed a sensitivity analysis excluding 
all studies with at least one high risk of bias rating within 
the remaining domains in the Cochrane Collaboration’s risk 
of bias tool (performance bias, detection bias, attrition bias, 
reporting bias, and other bias).
Most studies reported sufficient data on random sequence 
generation and allocation concealment. Gabbay et al51 
moved participants not receiving the intervention to the 
control group after randomization, resulting in an assess-
ment of high risk of bias. Studies providing comparable 
enhanced care for control group patients were judged at low 
risk of performance bias.36 Blinding of outcome assessors 
was explicitly reported in eight studies and insufficiently 
described in ten. We judged that insufficient blinding 
affected self-reported outcomes only. Most studies had 
inconsistencies between protocol and reported results, for 
example, insufficient information, nonreporting of specific 
outcomes due to nonsignificant results. Eight authors were 
contacted for missing information and one responded.47 
Funnel plots were inconclusive due to less than 10 studies 
in each assessed outcome.37
Diabetes distress
DD was a secondary outcome in all 18 studies; 16 of these 
reported complete results on DD. Tang et al. reported on 
selected subscales of the PAID scale only,56 while Welch et 
al. reported insufficient data.58 Two studies had follow-up 
at 3, 6, and 12 months;45,54 two at 3 and 6 months;47,55 one at 
6 and 12 months;50 and the remaining one single follow-up 
time point. Meta-analysis of seven studies showed a signifi-
cant reduction in DD at 3 months follow-up; SMD –0.18 
(95% CI –0.32, –0.03), P=0.02 (Figure 2). The quality of 
the evidence was low due to indirectness and imprecision 
(Supplementary material S1). Meta-analysis of eight studies 
showed a significant reduction in DD at 6 months follow-up; 
SMD –0.20 (95% CI −0.31, –0.08), P=0.006. The quality of 
the evidence was moderate primarily due to a serious risk 
of bias. Meta-analysis of six studies showed a significant 
reduction in DD at 12 months follow-up; SMD –0.21 (95% 
CI −0.34, –0.09), P=0.008. The quality of the evidence was 
moderate due to a serious risk of bias. Meta-analysis of two 
studies showed a significant reduction in DD at 24 months 
follow-up; SMD –0.21 (95% CI −0.36, –0.05), P=0.009. 
The quality of the evidence was low due to very serious 
risk of bias.
HbA1c
HbA1c was the primary outcome in 16 studies and a second-
ary outcome in two studies.42,50 One study had follow-up at 3, 
6, and 12 months;54 two at 3 and 6 months;47,55 two at 6 and 
12 months,50,56 and the remaining studies had one follow-up 
time point.
Meta-analysis of 18 studies showed no significant effect 
of interventions on HbA1c at any time of follow-up: MD 
–0.17 (95% CI –0.41, 0.06), P=0.14 at 3 months in six stud-
ies (low quality evidence; Figure 3; Supplementary material 
S2); MD –0.29 (95% CI −0.62, 0.05), P=0.09 at 6 months in 
nine studies (very low quality evidence); MD 0.02 (95% CI 
–0.17, 0.22), P=0.84 at 12 months in seven studies (moder-
ate quality evidence); and, MD –0.23 (95% CI –0.50, 0.04), 
P=0.10 at 24 months in two studies (low quality evidence).
Depression
Depression was a secondary outcome in six studies. Gabbay 
et al. used the Center for Epidemiologic Studies Depression 
Scale;51 five studies used the PHQ-9 scale.41,49,52,54,56 Four 
studies reported results on depression at 3,49 12,54 and 24 
months.51,52 Tang et al merely reported that there was no 
significant effect on depression.56 Sperl-Hillen et al did not 
provide results that allow mean + SD to be calculated.41 
Meta-analysis of four studies showed an SMD –0.20 (95% 
CI −0.33, –0.07), P=0.003 (forest plot not shown) in favor of 
the intervention at a mean of 16±10.2 months of follow-up. 
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The quality of evidence was low due to serious risk of bias 
(summary of findings table not shown).
Health-related quality of life
HRQOL was a secondary outcome in four studies.45,46,51,53 Bev-
erly et al measured HRQOL with diabetes QOL at 12 months 
follow-up,45 and Hermanns et al measured HRQOL with SF-12 
mental score at 6 months follow-up.46 Gabbay et al did not report 
results due to nonsignificance,51 while D’Eramo Melkus et al 
reported on selected subscales of QOL only.53 Meta-analysis 
of the two studies reporting results on HRQOL showed an 
SMD of –0.09 (95% CI –0.32, 0.14), P=0.46 in favor of the 
intervention at a mean follow-up of 9 months (forest plot not 
shown). The quality of evidence was low due to serious risk of 
bias and imprecision (summary of findings table not shown).
Subgroup analysis on DD
Subgroup analysis of studies according to intervention inten-
sity showed a significant reduction in DD of both intensive 
and brief interventions with the most pronounced effect after 
intensive intervention; intensive intervention SMD –0.20 
(95% CI −0.29, –0.11), P<0.001 and brief intervention SMD 
–0.17 (95% CI –0.32, –0.03), P=0.02. Subgroup analysis of 
studies according to individual vs group interventions showed 
a significant reduction in DD of both individual and group 
interventions with the most pronounced effect after individual 
Study or subgroup
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Test for overall effect: Z=3.34 (P=0.0008)
2.1.4 Diabetes distress at 24 months follow-up
Anderson 2009 20.2 18.9 118
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–0.24 (–0.44, –0.05)
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Test for overall effect: Z=2.63 (P=0.009)
Test for subgroup differences: 2=0.15, df=3 (P=0.98); I2=0%
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Figure 2 Meta-analysis: intervention vs standard care on diabetes distress at 3, 6, 12, and 24 months follow-up; (1) Means converted from scale with range 0-100 with positive 
outcomes reflecting a higher number; (2) 24 weeks follow-up; (3) SDs calculated from Cls using Revman 5.3; (4) Measured DDS at 8 months FU (ITT); (5) SDs calculated 
from SE using Revman 5.3; (6) Significant difference at baseline; PAID 59.9 intervention group versus 42.3 in the control group; (7) Means+SDs from Cochrane  review (Chew 
et al. 2017); (8) Measured with DDS at 9 months follow-up; (9) online care (intervention) versus web training (control); (10) Means+SDs from Cochrane  review (chew et 
al. 2017); (11) Measured with DDS (iTT). Risk of bias legend: (A) Random sequence generation (selection bias); (B) Allocation concealment (selection bias); (C) Blinding of 
participants and personnel (performance bias); (D) Blinding of outcome assessment (detection bias); (E) incomplete outcome data (attrition bias); (F) Selective reporting 
(reporting bias); (G) Other bias.
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intervention; SMD –0.25 (95% CI –0.36, –0.14), P<0.001 vs 
SMD –0.13 (−0.24, –0.02), P=0.02. Subgroup analysis of the 
three studies incorporating motivational interviewing showed 
a significant reduction in favor of motivational interviewing; 
SDM –0.25 (95% CI −0.39, –0.10), P=0.001 (Supplementary 
material S3; subgroup analyses DD).
Subgroup analysis on HbA1c
Meta-analysis of studies according to intervention intensity 
showed a reduction in HbA1c after intensive interventions, 
but deterioration after brief interventions; MD –0.23 (95% 
CI −0.44, –0.01), P=0.04 and MD 0.15 (95% CI –0.11, 0.40), 
P=0.26, respectively. Meta-analysis of studies according to 
individual vs group showed a reduction in HbA1c of indi-
vidual, but not group intervention; MD –0.15 (95% CI –0.45, 
0.15), P=0.34 and MD 0.02 (95% CI –0.18, 0.21), P=0.86, 
respectively. Meta-analysis of studies according to use of 
motivational interviewing showed a reduction of –0.08 (95% 
CI –0.43, 0.26), P=0.63 in favor of motivational interviewing 
(Supplementary material S4).
Sensitivity analysis
Removing six studies at high risk of attrition bias40,47,49,51–53 did 
not significantly change estimates of intervention effects on 
DD: SMD −0.25 (95% CI −0.55, 0.04) P=0.09 at 3 months, 
SMD –0.19 (95% CI −0.31, –0.08) P=0.001 at 6 months, and 
Study or subgroup
1.2.1 HbA1c at 3 months follow-up
7.8 1.7 87
22
44
97
70
25
7.9 1.9 19.1% –0.10 (–0.63, 0.43)
–0.10 (–1.80, 1.60)
–0.40 (–0.83, 0.03)
0.20 (–0.39, 0.79)
–0.17 (–0.41, 0.06)
–0.10 (–0.66, 0.46)
–0.30 (–0.86, 0.26)
1.9%
17.3%
28.7%
15.8%
17.3%
100.0%
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12
46
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68
24
317345
2.7
1.5
1.5
1.6
1
9.4
8.2
8.7
8.4
7.4
1.8
1.2
1.4
1.9
1
9.3
7.9
8.3
8.6
7.3
Heisler, 2014
Ing 2016
Kleinman 2017
Trief, 2016
Wagner 2016
Whittemore 2004
Subtotal (95% CI)
Heterogeneity: t2=0.00; c2=2.95, df=5 (P=0.71); I2=0%
Test for overall effect: Z=1.46 (P=0.14)
1.2.2 HbA1c at 6 months follow-up
7.9 1.2 85
44
58
56
193
97
7.8 1.5 11.9% 0.10 (–0.31, 0.51)
–0.30 (–0.84, 0.24)
–0.70 (–1.48, 0.08)
–0.70 (–1.04, –0.36)
–0.29 (–0.62, 0.05)
–0.20 (–0.63, 0.23)
–0.60 (–1.29, 0.09)
10.6%
9.1%
8.2%
12.7%
11.7%
100.0%
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46
54
57
189
78
823848
1.5
1.9
2.3
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1.4
8.2
9.5
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8.6
8.7
1.1
1.8
1.9
1.39
1.5
7.9
8.9
7.8
7.9
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90 0.50 (0.12, 0.88)12.2%941.298.11.358.6
200 –0.80 (–1.07, –0.53)13.3%1991.49.21.48.4
25 0.00 (–0.56, 0.56)10.4%2417.517.5
Hermanns 2011
McEwen 2017
Kleinman 2017
Trief, 2016 (2)
Spencer 2011 (1)
Welch 2011a (3)
Welch 2015 (4)
Whittemore 2004
Tang 2013
Subtotal (95% CI)
Heterogeneity: t2=0.20; c2=41.27, df=8 (P<0.00001); I2=81%
Test for overall effect: Z=1.68 (P=0.09)
1.2.3 HbA1c at 12 months follow-up
1.2.4 HbA1c at 24 months follow-up
8.54 1.4 58
40
56
51
489
186
8.1 1 14.7% 0.44 (0.00, 0.88)
–0.80 (–1.83, 0.23)
–0.10 (–0.66, 0.46)
0.10 (–0.13, 0.33)
0.02 (–0.17, 0.21)
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37
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2.4
2
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8
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Beverly 2013 (5)
McEwen 2017 (6)
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Tang 2013
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Trief 2016 (8)
Sperl-Hillen 2013 (7)
Subtotal (95% CI)
Heterogeneity: t2=0.02; c2=8.10, df=6 (P=0.23); I2=26%
Test for overall effect: Z=0.20 (P=0.84)
122
–0.23 (–0.50, 0.04)
–0.29 (–0.77, 0.19)33.1%
100.0%
126
359310
2.037.911.87.62
188 –0.20 (–0.54, 0.14)66.9%2331.881.77.8
Anderson 2009
Gabbay 2013
Subtotal (95% CI)
Heterogeneity: t2=0.00; c2=0.09, df=1 (P=0.76); I2=0%
Test for subgroup differences: c2=3.78, df=3 (P=0.29); I2=20.6%
Test for overall effect: Z=1.64 (P=0.10)
–2 –1 0 1 2
Intervention Standard care
Intervention Standard care Mean difference Risk of bias
IV, Random, 95% CI
Mean difference
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Figure 3 Meta-analysis: intervention vs standard care on HbA1c at 3, 6, 12, and 24 months follow-up; (1) SDs calculated from Ci using Revman 5.3; (2) At 8 months follow-
up (iTT); (3) Mean+SDs calculated from within group differences; (4) SDs Calculated from Se using Revman 5.3; (5) Means+SDs from Cochrance review (Chew et al. 2017); 
(6) At 9 months follow-up; (7) Means+SDs from Cochrance review (Chew et al. 2017); (8) iTT; Risk of bias legend; (A) Random sequence generation (selection bias); (B) 
Allocation concealment (selection bias); (C) Blinding of participants and personnel (performance bias); (D) Blinding of outcome assessment  (detection bias); (E) incomplete 
outcome data (attrition bias); (F) Selective reporting (reporting bias); (G) Other bias
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at 12 months, SMD –0.19 (95% CI −0.32, –0.06) P=0.005. 
Removing studies with at least one high risk of bias rating 
reduced effect estimates at 6 months, SMD –0.15 (95% CI 
–0.33, 0.03) P=0.10 and at 24 months, SMD –0.14 (95% CI 
–0.39, 0.11) P=0.28, while the effect estimates increased at 
3 months, SMD –0.26 (95% CI –0.44, 0.07) P=0.007 and 
at 12 months, SMD –0.23 (95% CI −0.38, –0.09) P=0.002.
Discussion
This review provided low to moderate quality evidence for 
small significant reductions in DD over time and very low 
to moderate quality evidence for no effect on HbA1c of 
psychosocial interventions. We found low quality evidence 
for a small reduction in depression, and moderate quality 
evidence for no effect on HRQOL.
The effect on DD was small (SMD <0.40);25 nevertheless, 
it may reflect a clinically significant improvement in a high-
risk population disproportionately affected by a clustering 
of risk factors and ensuing high risk of diabetes complica-
tions.8,59 The most distressed persons are also more likely to 
have high blood pressure60 and high LDL cholesterol,5 both 
factors equally important as HbA1c for prevention of micro- 
and macrovascular complications.61 There is evidence for 
an association between DD and adherence to medication.5,18 
Reducing DD and thereby increasing treatment adherence 
might be an intermediate pathway to preventing diabetes 
complications in this population. In a review also focusing 
on cognition- and emotion-focused interventions, Chew et 
al reported nonsignificant reductions in DD in a general 
population with T2DM.20 Our findings indicate that vulner-
able people with T2DM might benefit proportionately more 
from psychosocial interventions targeting DD.
The reduction in DD was not accompanied by a reduc-
tion in HbA1c. This opposed to Fisher et al,12 who reported 
a significant association between reduced DD and improved 
glycemic control during 18 months follow-up in a general 
T2DM population. Chew et al. reported a borderline sig-
nificant effect on HbA1c, but as previously mentioned, no 
effect on DD.20
The conflicting findings might be explained by the 
vulnerability criteria applied in this review including one 
or more comorbidities62 and longer duration of diabetes23 
which, pathophysiologically63 and mentally, might hamper 
possible effects of interventions on HbA1c despite reduced 
levels of DD. From an equity perspective, people with low 
socioeconomic status, low health literacy, and diabetes-
related sequelae may profit less from interventions, in spite 
of efforts to tailor interventions to their particular needs.64 
Hypothetically, not all interventions in included studies were 
optimally customized to this specific population. Further-
more, vulnerability may affect adherence to interventions 
in clinical trials.65 An implication of our findings could be 
stratified interventions for patients with low health literacy, 
social problems, and language and logistic barriers. This 
could accommodate access, attendance, and integration of 
interventions and potentially reduce attrition in this group of 
patients. Stratified interventions would likely require training 
of health care professionals in culturally and literacy sensitive 
aspects of person-centered diabetes care.
The lacking effect on HbA1c lends support to previ-
ous research suggesting a noncausal link between DD and 
HbA1c.13 However, provision of preintervention to all par-
ticipants prior to randomization in three studies40,49,54 and 
enhanced standard care to control groups in eleven stud-
ies40,42,44–47,49,52–54,58 might also have played a role. Previous 
trials have moreover suggested that behavioral interventions 
may be more effective in people with a poorer baseline psy-
chological state,66 while other studies link their effectiveness 
to having intervened on people with HbA1c≥9.0% (75 mmol/
mol).67 Indeed, the baseline levels of both DD (mean 39±10.8) 
and HbA1c 8.7% (mean 72±7.7) were clinically important 
in the studies included.68 Preinterventions and enhanced 
standard care may, however, have weakened the level to 
which DD and HbA1c could be reduced. This explanation is 
supported by the weaker effect of interventions at 3 months 
compared with 6 months contradictory to the well-established 
Hawthorne effect.69
There was low quality evidence from four studies for a 
small but significant reduction in depression. This lends sup-
port to the suggested link between depression and DD9 and 
may have clinical potential if there is an association between 
reduced depression and improved diabetes self-management, 
as previously reported.18 Our results may, however, reflect the 
instruments used to measure depression in included studies. 
According to Fisher et al, depression should be assessed 
using a gold standard structured clinical interview.11 Prefer-
ably, this approach should be used uniformly to distinguish 
depression from DD and direct care effectively.11 Despite 
the heterogeneous instruments used, studies have reported 
a disproportionate burden of depression in people with 
T2DM.70 Similar to our findings, other studies also failed to 
identify improvements in glycemic control despite reduction 
in depression.13,71
Exploratory subgroup analysis indicated a deteriorating 
effect of brief interventions on HbA1c. This could indicate 
that vulnerable people with T2DM benefit less from brief 
 
D
ia
be
te
s,
 M
et
ab
ol
ic 
Sy
nd
ro
m
e 
an
d 
O
be
sit
y:
 T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
98
.2
16
 o
n 
10
-J
an
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
30
Mathiesen et al
interventions, perhaps because they lack individualized 
peer support.72 This points toward a need for continuity and 
a designated health care professional as proposed in other 
studies.73,74 The explorative subgroup analyses of effects on 
DD of individual vs group and intensive vs brief interventions 
endorse this interpretation.
Subgroup analysis of interventions incorporating moti-
vational interviewing indicated a potential association with 
reduced DD. Again, this effect did not “spill over” on HbA1c, 
although it should be noted that only one of the studies 
included in the analysis identified an increase in HbA1c.57 
This study tested a brief intervention and was at high risk of 
bias, primarily due to attrition (35%).57
Our results lend support to the relevance of further 
research on person-centered care such as motivational inter-
viewing for reducing DD, and increasing glycemic control in 
vulnerable people with T2DM.21 Diverse theoretical founda-
tions determined the content of interventions. Notwithstand-
ing the value of theoretically founded interventions, there is 
some concern about a potential gap between theory and the 
implementation of person-centered care in clinical practice.75 
If interventions do not sufficiently reflect the theoretical 
foundation, effect may be weakened. Our review nevertheless 
adds further to the potential promise of person-centered care, 
eg, motivational interviewing including person-centered sup-
port from a devoted person for vulnerable people with T2D. 
Such approaches should consider the patients’ everyday life 
including their social network and life values.
Strengths and limitations
This review adhered to the Cochrane Collaboration’s meth-
odology for systematic reviews to rigorously examine the 
evidence for an effect of psychosocial interventions vs 
standard care on DD and, secondly, on HbA1c, depression, 
and HRQOL in vulnerable people with T2DM. Nonetheless, 
several factors might have influenced effect estimates.
We applied the SMD on outcomes where studies used 
different instruments for measuring DD, depression, and 
HRQOL. The application of the SMD has, however, been 
reported to be inaccurate and even erroneous76 due to data 
extraction errors, mistakes in calculations, or confusion 
regarding the direction of the included scales for specific 
outcomes. To avoid these pitfalls, our data extraction process 
was performed twice by each reviewer to ensure accuracy. 
Moreover, we used Review Manager to perform calculations 
and chose to include only studies using validated instruments 
(PAID and DDS).
Secondly, sensitivity analysis revealed that removing stud-
ies with high risk of bias reduced effect estimates on DD at 
6 and 24 months follow-up, while they increased at 3 and 12 
months. The results remained statically significant at 3 and 
12 months follow-up only. This differs from the findings of 
Savovic et al, who concluded that low quality studies are more 
likely to report large effect sizes.77 Removing studies with 
high attrition marginally attenuated effect estimates on DD. 
This might indicate a minor overestimation of effect sizes 
due to high attrition. However, the effect on DD at 6 and 12 
months remained statistically significant.
Thirdly, poor reporting of results and missing information 
resulted in an assessment of most studies as being at “unclear” 
risk of bias. Likewise, in studies with insufficient reporting, 
some authors stated that lack of reported results was due to 
nonsignificant differences between groups at follow-up.56 
Consequently, studies showing no increase or decrease in 
outcomes were not included in meta-analyses, potentially 
leading to overestimation of effects. Inclusion of a wait-list 
design in three studies might have induced anticipation bias 
and reduced between-group differences at follow-up. More-
over, the use of available case analysis may have augmented 
the effect on all outcomes.
Baseline DD values differed significantly between the 
intervention and the control groups in four studies.47,48,55,44 
Due to nonreporting of change scores in eleven stud-
ies41,45,47–51,53–56 and the use of different instruments for 
measuring DD, we considered that post hoc exploratory 
analyses using available change scores would be misleading.25 
Moreover, imbalance between groups at baseline should be 
eliminated in meta-analysis.36
If the effects of emotion- vs cognition-based interventions 
could be distinguished, it might have strengthened the review. 
However, some of the most cited theoretical models underly-
ing the interventions, eg, Bandura’s model on self-efficacy,30,31 
involve both emotion- and cognition-based constructs. There-
fore, we were unable to distinguish effects of interventions 
according to underlying theory. The generalizability of our 
findings might be limited by the inclusion of only two studies 
originating from other countries than United States.
Conclusion
We found low to moderate quality evidence for a significant, 
but small reduction in DD and very low to moderate quality 
evidence for no effect on HbA1c at 3, 6, 12, and 24 months 
follow-up of psychosocial interventions. The reduction in 
depression was significant, but small, while there was no 
effect on HRQOL. Exploratory subgroup analyses showed 
significant incremental reductions in DD and HbA1c of 
intensive (>4 sessions) vs brief interventions. On HbA1c, 
there was a nonsignificant trend toward deteriorating HbA1c 
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after brief intervention. Individual and group interventions 
significantly reduced DD, but not HbA1c. On both outcomes 
the largest reductions were found after individual interven-
tions. Subgroup analysis of interventions using motivational 
interviewing was associated with larger effects on DD, but 
not on HbA1c.
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